A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.
description
Transcript of A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.
![Page 1: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/1.jpg)
A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine)
In Sarcoma.
E.Anders Kolb, Pooja Gidwani, Robert Peter Gale, Richard Gorlick
![Page 2: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/2.jpg)
Isophosphoramide Mustard-lysine (Zio-201)
• IPM: active moiety of ifosfamide.
• Alkylator: crosslinks DNA via G:C base pairs irreversibly.
• Activity: variety of cancers.
• Unstable for clinical administration.
• Lysine: provides stability.
![Page 3: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/3.jpg)
Metabolism of Oxazaphosphorines
![Page 4: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/4.jpg)
Ifosfamide Versus Zio-201
Chloroacetaldehyde“fuzzy brain”
Acrolein“bladder toxicity”
IFOS
X XZio-201
Courtesy of ZiopharmCourtesy of Ziopharm
![Page 5: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/5.jpg)
Advantages of Zio-201
• Effective
• No toxic metabolites (acrolein, CAA)
• Bypassing resistance mechanisms (ALDH over-expression)
![Page 6: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/6.jpg)
Objectives
• To test the activity of Zio-201 in a broad variety of sarcomas in-vitro.
• To test the activity of Zio-201 in sarcoma tumor xenografts including cyclophosphamide resistant tumors.
![Page 7: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/7.jpg)
0
0.5
1
0.01 0.1 1 10 100
Concentration (mcg/ml)
Via
bil
ity
(O
D-T
/OD
-C)
RD
RH30
0
0.5
1
0.01 0.1 1 10 100
Concentration (mcg/ml)
Via
bil
ity
(O
D-T
/OD
-C)
OS230
OS229
OS222
SaOS
0
0.5
1
0.01 0.1 1 10 100
Concentration (mcg/ml)
Via
bil
ity
(O
D-T
/OD
-C)
SYO1
HSSYII
0
0.5
1
0.01 0.1 1 10 100
Concentration (mcg/ml)
Via
bil
ity
(O
D-T
/OD
-C)
SKES1
SKPNDW
a. Rhabdomyosarcoma b. Ewing’s Sarcoma
c. Osteosarcoma d. Synovial Sarcoma
Zio-201 has Broad Activity in Sarcoma Lines In Vitro
![Page 8: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/8.jpg)
0
0.5
1
0.01 0.1 1 10 100 1000
Concentration (mcg/ml)
Via
bil
ity
(T
-OD
/C-O
D)
Daily x 1
Daily x 3
RH30-Rhabdomyosarcoma
0
0.5
1
0.01 0.1 1 10 100 1000
Concentration (mcg/ml)
Via
bil
ity
(O
D-T
/OD
-C)
Daily x 1
Daily x 3
OS229-Osteosarcoma
In Vitro, in most lines evaluated, the IC50 of daily x1 and daily x3 dosing are comparable
![Page 9: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/9.jpg)
In Vitro, in most lines evaluated, the IC50 of daily x1 and daily x3 dosing are comparable
Cell Line Histology Daily x 3 IC50 Daily x 1 IC50
SK-PN-DW Ewing’s Sarcoma 0.44 µg/ml 1.13 µg/ml
SK-ES-1 Ewing’s Sarcoma 0.31 µg/ml 1.01 µg/ml
RH30 Alveolar Rhabdomyosarcoma 0.85 µg/ml 0.86 µg/ml
RD Embryonal Rhabdomyosarcoma 1.02 µg/ml 0.99 µg/ml
SYO-1 Synovial Sarcoma 0.080 µg/ml 0.16 µg/ml
HSSY-II Synovial Sarcoma 0.45 µg/ml 0.45 µg/ml
SaOS Osteosarcoma 1.08 µg/ml 1.23 µg/ml
OS222 Osteosarcoma 1.21 µg/ml 7.0 µg/ml
OS229 Osteosarcoma 0.31 µg/ml 0.50 µg/ml
OS230 Osteosarcoma 1.09 µg/ml 1.50 µg/ml
![Page 10: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/10.jpg)
0.1
1
10
0 7 14 21 28 35 42
Time (days)
Rel
ativ
e T
um
or
Vo
lum
e
Control175mg/kg daily x 1 days 1 and 21100mg/kg daily x 3 starting days 1 and 21
In the OS31 osteosarcoma tumor line, Zio-201 at the MTD for each dose schedule results in significant tumor growth
delay
p=0.09
![Page 11: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/11.jpg)
Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu1 J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA. The Pediatric Preclinical Testing Program: Description of Models and Early Testing Results. Pediatric Blood and Cancer (in press)
Cyclophosphamide resistance in Osteosarcoma Lines
OS31 OS33
![Page 12: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/12.jpg)
Aldehyde dehydrogenase 3A1 is differentially expressed in
cyclophosphamide-resistant lines compared to sensitive lines
Affy U133a Micorarray data courtesy of Peter Houghton, PI, Pediatric Preclinical Testing Program,St. Judes Children’s Research Hospital
OS
160
OS
1
OS
17O
S2
OS
29O
S31
OS
33O
S9
ALD3A1
![Page 13: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/13.jpg)
0.1
1
10
0 7 14 21 28 35 42
Time (weeks)
Rel
ativ
e T
um
or
Vo
lum
e
Control
100mg/kg daily x3
1 2 3 4 5 60
Zio-201 is active in the cyclophosphamide-resistant, ALD3A1-overexpressing OS31 line
![Page 14: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/14.jpg)
Summary• Zio-201 has broad activity in sarcomas in-
vitro.
• In many cell lines, IC50 for daily x1 and daily x3 dosing are comparable.
• Significant responses are noted in OS 31 osteosarcoma tumor line in-vivo at both daily x1 and daily x3 dosing.
![Page 15: A PRECLINICAL Evaluation Of ZIO-201 (ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma.](https://reader035.fdocuments.net/reader035/viewer/2022062800/5681403d550346895dabaea2/html5/thumbnails/15.jpg)
Summary
• ALD3A1 is overexpressed in cyclophosphamide resistant tumors (OS31, OS2) suggesting this as a potential mechanism of resistance.
• IPM-lysine is active in cyclophosphamide resistant OS31 line.